ELOVL4 is a Prognostic Biomarker with Implications for Immune Modulation and Therapeutic Response in Gastric Cancer
Our findings establish ELOVL4 as a biomarker for poor prognosis and therapeutic target in GC, with implications for prognosis evaluation, immune microenvironment modulation, and chemotherapeutic response.
Authors
- Yuxin Chu (ORCID: https://orcid.org/0000-0001-5526-997X)
- Qibin Song (ORCID: https://orcid.org/0000-0003-2387-6438)
- Yi Yao (ORCID: https://orcid.org/0000-0003-2601-9423)
Institutions
- Wuhan University (CN)
- Renmin Hospital of Wuhan University (CN)
Publication Details
- Journal
- Current Molecular Medicine
- Published
- 2025-10-02
- DOI
- https://doi.org/10.2174/0115665240356824250116103049
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00